Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies

被引:1
作者
Sayar, H. [2 ]
Shen, Z. [3 ]
Lee, S. J. [1 ]
Royce, M. [1 ]
Rabinowitz, I. [1 ]
Lee, F. [1 ]
Smith, H. [4 ]
Eberhardt, S. [1 ]
Maestas, A. [1 ]
Lu, H. [3 ]
Verschraegen, C. [1 ]
机构
[1] Univ New Mexico, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA
[2] Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA
[3] UMDNJ Robert Wood Johnson Med Sch, Inst Canc, Dept Radiat Oncol, New Brunswick, NJ USA
[4] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA
关键词
Cisplatin; Capecitabine; Irinotecan; DNA adducts; Phase I; METASTATIC COLORECTAL-CANCER; 1ST-LINE CHEMOTHERAPY; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; REPAIR; CELLS;
D O I
10.1007/s10637-008-9172-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This phase I trial assessed the safety and the maximum tolerated dose of capecitabine given for 10 days prior to a combination of cisplatin and irinotecan in patients with advanced solid malignancies. It also evaluated the changes in cisplatin DNA adducts induced by capecitabine. Patients and Methods: Patients with refractory solid tumors who had not failed 5-fluorouracil (5-FU) analogs or topoisomerase I inhibitors were eligible. All cohorts of patients first received a 28-day cycle of cisplatin and irinotecan. Both drugs were given at a dose of 50 mg/m(2) intravenously on day 1, followed by irinotecan on days 8 and 15 at the same dose. The first cycle served as an internal control. Starting from the second cycle, patients received increasing doses per cohort of capecitabine from day 1 to 10 of each cycle, followed by cisplatin on day 11 and irinotecan on days 11, 18 and 25, both at same doses as the first cycle. Cycles were repeated every 38 days. The starting dose of capecitabine was 500 mg/m(2)/day which was escalated by 250 mg/m(2)/day in the subsequent cohort of patients to reach the maximum tolerated dose (MTD). Later, additional patients were treated at the MTD of capecitabine to further evaluate the safety, pharmacodynamics, and tumor response. Patients blood was tested for cisplatin-DNA adducts to determine the impact of capecitabine on cisplatin-based therapy. Results: Fifteen patients received at least 2 cycles of treatment. At 1,250 mg/m(2), two DLT of prolonged neutropenia of grade a parts per thousand yen3 were observed. The MTD for capecitabine was thus determined to be 1000 mg/m(2)/day. Fatigue and diarrhea of grade 1 or 2 were the most frequent toxicities at this dose level. No significant hematologic toxicity was observed at the MTD. Two complete and three partial remissions were observed. Four of the responders had received a platinum agent and/or 5-FU in the past. Conclusions: A sequential treatment with capecitabine followed by cisplatin and irinotecan is well tolerated and demonstrates clinical activity in patients with advanced solid malignancies. The influence of capecitabine, if any, on the efficacy of the cisplatin-irinotecan combination is not related to a variation in cisplatin-DNA adducts.
引用
收藏
页码:153 / 158
页数:6
相关论文
共 14 条
  • [1] The discovery and development of cisplatin
    Alderden, RA
    Hall, MD
    Hambley, TW
    [J]. JOURNAL OF CHEMICAL EDUCATION, 2006, 83 (05) : 728 - 734
  • [2] Baldwin J, 2002, J NATL CANCER I, V94, P1191
  • [3] Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer
    Boku, N
    Ohtsu, A
    Shimada, Y
    Shirao, K
    Seki, S
    Saito, H
    Sakata, Y
    Hyodo, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 319 - 323
  • [4] Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer
    Chitapanarux, I
    Tonusin, A
    Sukthomya, V
    Charuchinda, C
    Pukanhapan, N
    Lorvidhaya, V
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 89 (03) : 402 - 407
  • [5] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    de Gramont, A
    Figer, A
    Seymour, M
    Homerin, M
    Hmissi, A
    Cassidy, J
    Boni, C
    Cortes-Funes, H
    Cervantes, A
    Freyer, G
    Papamichael, D
    Le Bail, N
    Louvet, C
    Hendler, D
    de Braud, F
    Wilson, C
    Morvan, F
    Bonetti, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 2938 - 2947
  • [6] RADIOSENSITIZATION OF CULTURED HUMAN COLON ADENOCARCINOMA CELLS BY 5-FLUOROURACIL - EFFECTS ON CELL-SURVIVAL, DNA-REPAIR, AND CELL RECOVERY
    HUGHES, LL
    LUENGAS, J
    RICH, TA
    MURRAY, D
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 23 (05): : 983 - 991
  • [7] Jacob S, 2001, CANCER RES, V61, P6555
  • [8] Pharmacology of Topoisomerase I Inhibitors Irinotecan (CPT-11) and Topotecan
    Mathijssen, Ron H. J.
    Loos, Walter J.
    Verweij, Jaap
    Sparreboom, Alex
    [J]. CURRENT CANCER DRUG TARGETS, 2002, 2 (02) : 103 - 123
  • [9] Oxaliplatin clinical activity: a review
    Misset, JL
    Bleiberg, H
    Sutherland, W
    Bekradda, M
    Cvitkovic, E
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 35 (02) : 75 - 93
  • [10] Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
    Noda, W
    Nishiwaki, Y
    Kawahara, M
    Negoro, S
    Sugiura, T
    Yokoyama, A
    Fukuoka, M
    Mori, K
    Watanabe, K
    Tamura, T
    Yamamoto, S
    Saijo, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02) : 85 - 91